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Intellectual disability (ID) is a rare neurodevelopmental disorder estimated to 
affect at least 1% of the population. ID is defined as “a disorder with onset during 
the developmental period that includes both intellectual and adaptive functioning 
deficits in conceptual, social and practical domains. ID is a complex and highly 
variable disorder, often associated with a number of other conditions such as 
microcephaly and neurological impairment. Identifying genes responsible for ID will 
not only aid diagnosis and genetic counselling efforts, but also elevate our 
understanding of the complex mechanisms and genes crucial for normal brain 
development.  
 
Consanguineous populations are often enriched for autosomal recessive 
disorders such as ID. With this in mind, an investigative strategy was designed to 
identify the underlying genetic cause of ID within four families identified through 
an ongoing translational community research program based at UEMS. Each 
family has at least two individuals affected with varying ID phenotypes. Single 
nucleotide polymorphism mapping and whole exome sequencing was used to 
identify potential candidate pathogenic variants within shared autozygous regions 
and genome wide. 
 
 
A putative diagnosis has been made within two of the families, with one family 
harbouring a known variant within ALG1; which is known to cause a rare 
autosomal recessive congenital disorder of glycosylation, and the other family 
harbouring a novel variant within an ARHGAP gene; which has recently been 
implicated in neurodevelopmental disorders. The other two families require 
further research, however potential novel variants as well as chromosomal 
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variations have been identified. Through this collaborative study we have shown 
how important community-based research programmes are in defining the 




List of Tables .......................................................................................................... 8 
List of Figures ......................................................................................................... 9 
 
1. INTRODUCTION .............................................................................................. 11 
1.1 Classification of Intellectual Disability ....................................................... 11 
1.2 The Cost of Intellectual Disability .............................................................. 14 
1.3 Microcephaly ............................................................................................. 16 
1.4 The Genetics of Intellectual Disability and Microcephaly  ......................... 18 
1.5 The Role of Community-Based Programs to Define Genetic Causes of ID    
  .................................................................................................................. 21 
1.6 Aims .......................................................................................................... 24 
 
2. SUBJECTS AND METHODS .......................................................................... 25 
2.1 Single nucleotide polymorphism (SNP) genotyping .................................. 25 
2.2 Primer Design ........................................................................................... 25 
2.3 Polymerase Chain Reaction (PCR) .......................................................... 26 
2.4 Primer optimisation ................................................................................... 27 
2.5 Agarose gel electrophoresis ..................................................................... 27 
2.6 EXOSAP Purification of PCR product ....................................................... 29 






3. RESULTS ........................................................................................................ 30 
3.1 Sequence alteration of ALG1 associated with a congenital disorder of 
glycosylation .............................................................................................. 30 
3.2 Defining mutations within an ARHGAP molecule as a likely new cause of 
ID ............................................................................................................... 37 
3.3 Exome sequencing identifies new candidate genetic causes of ID in an 
extended family with individuals with this disorder .................................... 42 
3.4 Further genetic studies are required to determine the cause of ID in an 
extended family with multiple individuals with this disorder ....................... 49 
 
4. DISCUSSION ................................................................................................... 54 
 
5. FUTURE WORK .............................................................................................. 67 
 
6. CONCLUSION ................................................................................................. 69 
 
7. APPENDICIES ................................................................................................. 71 
7.1 Primer Sequences .................................................................................... 71 
 




List of Tables 
Table 2-1 Components of standard 10 μl PCR tube .......................................... 27 
Table 2-2. 50x LAB buffer solution composition ................................................ 28 
Table 3-1 Largest regions of autozygosity common to affected members in 
Family 2 ............................................................................................................. 32 
Table 3-2 Candidate/ Primary ID genes identified within the largest region of 
autozygosity from SysID for Family 1 ................................................................ 33 
Table 3-3 Novel and rare homozygous variants identified from whole exome 
sequencing of VI:3 ............................................................................................. 35 
Table 3-4 Largest regions of autozygosity common to affected members in 
Family 2 ............................................................................................................. 38 
Table 3-5. Novel and rare homozygous variants identified from whole exome 
sequencing of VI:1 ............................................................................................. 40 
Table 3-6 Largest regions of autozygosity common to affected members in 
Family 3 ............................................................................................................. 44 
Table 3-7 Candidate/ Primary ID genes identified within the largest region of 
autozygosity from SysID for Family 3 ................................................................ 46 
Table 3-8 Novel and rare homozygous variants identified from whole exome 
sequencing of VI:1 ............................................................................................. 47 
Table 3-9 Novel and rare compound heterozygous variants identified from 
whole exome sequencing of VI:1 ....................................................................... 47 
Table 3-10. Largest regions of autozygosity common to affected members of 
Family 4 ............................................................................................................. 51 
Table 3-11. Novel and rare homozygous variants identified from whole exome 
sequencing of VI:8 ............................................................................................. 53 
9  
Table 3-12. Novel and rare compound heterozygous variants identified from 
whole exome sequencing of VI:8 ....................................................................... 53 
 
List of Figures 
 
Figure 1-1. DSM-V classification of neurodevelopmental disorders (APA 2013) 
 
......................................................................................................................... 12 
Figure 1-2 Typical Head Size, Microcephaly and Severe Microcephaly 
Comparison. Taken from (Petersen et al. 2016) ................................................ 17 
Figure 3-1. Family 1 Pedigree ........................................................................... 30 
Figure 3-2. Visual depiction of largest autozygous regions of the genome 
(shown in red) common to all three affected siblings in Family 1 ...................... 31 
Figure 3-3 Figure 3-3 Sequencing chromatogram from a parental heterozygous 
carrier for the ALG1 c.826C>T gene variant, showing both the alternate (T) and 
wildtype (C) alleles  ............................................................................................ 36 
Figure 3-4 Family 2 Pedigree ............................................................................ 37 
Figure 3-5. Visual depiction of largest autozygous regions of the genome 
(shown in red) common to affected siblings in Family 2 .................................... 38 
Figure 3-6 Sequencing chromatograms for ARHGAP c.1673C>T gene variant41 
Figure 3-7 Family 3 pedigree ............................................................................. 42 
Figure 3-9 Visual depiction of largest autozygous regions of the genome (shown 
in red) common to all three affected siblings in Family 3 ................................... 43 
Figure 3-8 Karyotyping of three affected individuals within Family 3 to identify 
shared CNV's (highlighted by red box) .............................................................. 43 
Figure 3-10 Family 4 pedigree ........................................................................... 49 
Figure 3-11 Karyotyping of three affected individuals within Family 4 to identify 
shared CNV's (highlighted by red box) .............................................................. 50 
10  
Figure 3-12 Visual depiction of largest autozygous regions of the genome 
(shown in red) common to affected siblings in Family 4 .................................... 51 
Figure 4-1 Expression of ARHGAP as per UCSC Genome Browser (Website: 
https://genome.ucsc.edu/cgi-bin/hgGateway) .................................................... 58 
Figure 4-2 ARHGAP interaction as per STRING version 10.5 ........................... 59 
Figure 4-3 Visual representation of the overlap between the reported 17q21.31 
duplications and the duplication identified within Family 3 ................................. 62 
Figure 4-4 Expression of SALL3 as per UCSC Genome Browser (Website: 
https://genome.ucsc.edu/cgi-bin/hgGateway) .................................................... 63 
Figure 4-5 Chromosome 14 duplication location comparison between Family 4 




1.1 Classification of Intellectual Disability 
 
Intellectual disability (ID) is estimated to affect at least 1% of the population 
(Harris 2006), with The American Association on Intellectual and Developmental 
Disabilities defining it as ‘a disability characterised by significant limitations in both 
intellectual functioning and adaptive behaviour, originating before the age of 18’ 
(Vannest 2014) . The nomenclature of ID has evolved over time, with terms such 
as “mental retardation” previously being used. Intellectual disability is currently 
recommended as the best term to describe a disability resulting from the 
impairment of cognitive functions and adaptive behaviour with an early onset 
(Chiurazzi and Pirozzi 2016). Classification of mental disorders (psychiatric 
nosology) has typically been done by psychiatrists. The two most widely used 
classification systems for mental disorders are ICD and DSM. 
 
 
The International Statistical Classification of Diseases and Related Health 
Problems (ICD) is readily available on the worldwide web, and was founded by 
the World Health Organisation (WHO) in 1948. The most recent edition, ICD-11, 
was released on 18th June 2018, with the aim of being implemented by the 1st 
January 2022 following endorsement after the 72nd World Health Assembly in 
2019. More than 100 countries use ICD, allowing for a wealth of information to be 
shared globally regarding health trends and statistics. The use of ICD is becoming 
increasingly popular within the field of clinical care and research in defining and 
studying diseases. 
 
The American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders (DSM) is published by the American Psychiatric Association 
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(APA). In 1844 APA published a statistical classification of institutionalised patients 
with mental disorders, with the aim to improve communication between 
institutions regarding the different disorders they saw. This first publication has 
evolved over time into the DSM diagnostic classification system known today. The 
DSM is now in its fifth edition, the DSM-5, which was published in May 2013. 
Unlike the ICD, which covers health as a whole, the DSM only aims to classify 
mental health disorders. The classification of intellectual disability within DSM-V 
is summarised within Figure 1-1 (APA 2013). 
 




Although both the ICD and DSM have proven enormously beneficial in providing 
a common language for communication, discrepancies within the definitions of 
categories between the two classification systems may actually be impeding 
international communication and research (First 2009). Both APA and WHO have 
agreed that a harmonisation between the two systems should be implemented, 
with a “DSM–ICD Harmonisation Coordinating Group” consisting of both DSM and 
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ICD members being tasked with this effort.  
 
Within ICD-11 intellectual disability is referred to as a “disorder of intellectual 
development” and can be found within chapter 6 - Mental, behavioural or 
neurodevelopmental disorders, subsection: 6A00 Disorders of intellectual 
development. A disorder of intellectual development is defined as a condition 
“originating during the developmental period characterized by significantly below 
average intellectual functioning and adaptive behaviour that are approximately two 
or more standard deviations below the mean, based on appropriately normed, 
individually administered standardised tests”. Disorders of intellectual 
development can be subdivided into mild, moderate, severe, profound, and 
provisional, dependent on the number of standard deviations the individual differs 
from the mean, as well as age. 
 
Conversely, DSM-5 emphasises the importance of using other methods of 
diagnosis, such as adaptive functioning, instead of relying on standardised tests 
such as IQ. By placing less weight on IQ scores and focusing more on conceptual, 
social, and practical domains, it was hoped that a more accurate and 
comprehensive description of how an individual’s deficit in mental abilities may 
affect their ability to function in day-to-day life would be established. DSM-5 states 
that three criteria must be met for a diagnosis of intellectual disability: (A) deficits 
in general intellectual functioning, (B) deficits in everyday adaptive functioning and 
(C) onset of these deficits in the developmental period. In keeping with ICD- 11, 
DSM-5 also subdivides intellectual disability into mild, moderate, severe and 
profound, with the severity determined by adaptive functioning. Comparing these 
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two systems and how they classify intellectual disability, it is clear that the DSM- 
5 places a lot more value on how a deficiency in intellectual functioning may 
impact the lives of the individuals.  
 
Another term often confused with intellectual disability is developmental delay. 
Developmental delay can either be specific (only one area of development is 
affected), or global (more than one developmental domain is significantly 
affected). As stated in DSM-5, developmental delay is a term used only for 
individuals bellow the age of five. These children may be slow to reach certain 
developmental milestones, such as speech and language, social skills and motor 
skills, however as a child under the age of five may not be able to complete all 
the necessary assessments to ascertain a diagnosis of intellectual disability, the 
term developmental delay is used. A diagnosis of developmental delay does not 
preclude intellectual disability. Children with intellectual disability will experience 
developmental delay, however not all children with developmental delay will have 
intellectual disability. 
 
1.2 The Cost of Intellectual Disability 
 
The average cost of living for an older person diagnosed with ID is estimated to 
be around £790 a week in the UK (Strydom et al. 2010), which is more than 
double the basic income of £300 a week for a full time employee earning a 
minimum wage. Almost 90% of the participants of the study by Strydom et al 
relied on benefits for their income. This dependency on benefits leads to around 
5% of the total care budget being used to care for older adults with ID. ID and 
psychiatric disorders represent the biggest share of healthcare costs in the 
Netherlands (J. J. Polder et al. 2002), a representation most likely paralleled 
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within other developed countries. The cost of living with an autism spectrum 
disorder increases by more than 1.5 times when also diagnosed with intellectual 
disability (Knapp, Romeo, and Beecham 2009), further highlighting the cost 
implications of living with ID. 
 
The increased costs associated with intellectual disability may be due in part to 
inequalities in healthcare. Emerson et al identified the five main sources of health 
inequalities for people with ID (Emerson et al. 2011): 
 
1. Greater risk of exposure to social determinants of poorer health such as 
poverty, poor housing, unemployment and social disconnectedness. 
 
2. Increased risk of health problems associated with specific genetic and 
biological causes of learning disabilities. 
 
3. Communication difficulties and reduced health literacy. 
 
4. Personal health risks and behaviours such as poor diet and lack of 
exercise. 
 




These inequalities, although resulting in increased costs and a decreased 
standard of care and quality of life for ID patients, may also place many NHS 
Trusts in breach of the Equality Act 2010, the Mental Capacity Act 2005 and the 
Health and Social Care Act 2008. 
 
As pointed out by Emerson et al, ID also comes with increased risks of other 
health issues. It has been shown that dementia occurs at a much higher rate 
among people with ID compared to older adults without (Cooper 1997) (Strydom 
et al. 2007). Epilepsy is a condition that can greatly affect the lives of the 
individuals and their families/ carers, and is more prevalent in people with ID 
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(Bowley and Kerr 2000). Having an ID also increases the likelihood of either being 
misdiagnosed for epilepsy or not being diagnosed at all (Chapman et al. 2011) 




Many of the inequalities faced by patients with ID could be prevented or at the 
very least identified with improved education of practitioners regarding the care 
of ID patients, as well as consistent and personal health care. The Annual Health 
Check is a scheme aimed at people registered by their GP as having ID. This 
scheme entitles registered patients to a free health check every year. The 
possible benefits of this scheme are clear, however for there to be a real impact 
on the lives of patients and better cost effective care, a more robust database of 
patients diagnosed with ID needs to be collated, as well as ensuring all patients 
attend their annual health check. In addition, further research into understanding 





Neurodevelopmental disorders such as ID can be characterised by defective 
neuronal development, in particular, abnormalities within dendritic spines 
(Kaufmann and Moser 2000). Correct brain development relies on a complicated 
and delicate balance between gene expression and environmental inputs (Stiles 
and Jernigan 2010). The basic structures of the brain and central nervous system 
are established by the end of the embryonic period, with neuron production 
beginning 42 days post conception (Bystron, Blakemore, and Rakic 2008). An 
individual neuron can connect to more than 1,000 other neurons via synapses, 
and these neuron connection networks process all the information relating to our 
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thoughts, feelings, memories, sensations and actions. It is therefore unsurprising 
that abnormal brain growth and development have been linked to a vast amount 
of disabilities (Mirzaa and Paciorkowski 2014). 
 
 
Primary Microcephaly is a defect identifiable at birth in which the baby’s head is 
much smaller than expected (Figure 1-2), and can result in the formation of 
defective dendrites and dendritic structures. Microcephaly is therefore a common 
phenotype of children with intellectual disability (Watemberg et al. 2002). There 
are a number of different environmental factors that can lead to microcephaly. 
Exposure to alcohol or toxic chemicals during pregnancy, severe malnutrition, 
viruses/ infections and genetic changes are all aetiologies of microcephaly.  
Figure 1-2 Typical Head Size, Microcephaly and Severe Microcephaly Comparison. Taken from (Petersen 
et al. 2016) 
 
Environmental factors are an important cause of ID and may typically be 
preventable with a healthy lifestyle and access to a good standard of healthcare, 
as shown by a population study in Mumbai, India carried out by U. Dave et al in 
2005. Their study identified 511 confirmed ID cases, 251 of which were caused by 
potentially preventable environmental factors, such as birth asphyxia, infections 
and low birth weight (Dave, Shetty and Mehta 2005). This highlights the necessity 
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to improve education and healthcare availability in developing countries.  
 
1.4 The Genetics of Intellectual Disability and Microcephaly  
~40-50% of moderate to severe cases of ID are thought to be linked to a genetic 
cause (Pavlowsky, Chelly, and Billuart 2012). The five most common types of ID 
are; Down syndrome, Williams syndrome, Angelman syndrome, Prader-Willi 
syndrome and Fragile X syndrome. All of these syndromes involve a known genetic 
cause. Down syndrome is a result of trisomy 21, which causes each cell in the 
body to have 47 chromosomes instead of the usual 46. Williams’ syndrome is an 
autosomal dominant condition caused by a deletion mutation in chromosome 7. 
Angelman and Prader-Willi syndromes are a result of genomic imprinting; a 
phenomenon caused by parentally specific differential gene expression, and 




It has been estimated that the number of genes affecting cognition is 3.5 times 
greater on the X chromosome than on other chromosomes (Ulrich Zechner et al. 
2001). One line of research has focused towards X-linked ID genetic mutations 
(Hu et al. 2016) (Piton, Redin, and Mandel 2013) due to the often recessive 
nature of ID and males being hemizygous for that chromosome. By 2012, 102 X- 
linked genes had been linked to 81 X-linked ID syndromes (Lubs, Stevenson, and 
Schwartz 2012), although this number is likely to increase year by year. Any 
apparent increased density of “intelligence genes” within the X-chromosome may 
be due to sexual selection during evolution, and may explain why there is greater
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variability in male IQ scores. (Graves, Gecz, and Hameister 2002) (Johnson, 
Carothers, and Deary 2008). However, until every ID gene has been identified, it 
is clearly difficult to know for certain whether there is in fact a higher concentration 




Through research centred predominantly on large, consanguineous families, 
many monogenic genetic causes of ID have been identified. The most recent 
update of SysID on the 14th June 2018 (a database cataloguing ID genes, 
Website: https://sysid.cmbi.umcn.nl/) lists 1,108 primary ID genes (genes that are 
published and have been confirmed to cause intellectual disability), and 808 
candidate ID genes (Kochinke et al. 2016). Identifying monogenic causes of ID 
relies on there being a large sample size of individuals all with the same ID 
disorder. As the presentation of ID may be highly variable and overlapping, it can 
be difficult to definitively determine whether patients, often even within the same 
family, may have ID due to the same genetic cause. These issues may be 
circumvented to a degree when investigating the cause of ID in large (often 
consanguineous) families, where it is more likely that affected individuals will 
harbour the same pathogenic variant(s). 
 
 
Research into the genetic causes of microcephaly has helped shed light on genes 
and proteins vital for normal brain development. Research into autosomal 
recessive primary microcephaly (MCPH) has indicated that the genes involved in 
this disorder may have played a role in the evolutionary expansion of the primate 
brain (Cox et al. 2006). To date, twelve MCPH loci have been mapped (Faheem 
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et al. 2015), however there will be many more syndromes in which microcephaly 
is a feature. 
 
 
Precise regulation of the mitotic activity of neuronal progenitor cells is critical for 
correct development of neurons (Rakic 1988), therefore disruption of mitosis is 
likely to cause cortical disorders such as microcephaly. Many of the MCPH genes 
identified play a role in mitosis. For example, microcephalin (MCPH1) a known 
genetic cause of microcephaly, is involved in chromosomal condensation (Cox et 
al. 2006), ASPM is important for the orientation of mitotic spindles (do Carmo 
Avides and and Glove 1999) and CENPJ controls the length of centrioles (Hung 
et al. 2004), to name a few. Increased research into the genetic aetiology of 
MCPH has improved genetic testing and patient management of the condition, 
as well as improved scientific understanding of human brain development. 
 
 
In 2002, Kelley et al reported a recessive form of microcephaly found within the 
Old Order Amish of Lancaster County (Kelley et al. 2002), due to a substitution 
(c.530G>C) mutation within SLC25A19. The SLC25A19 gene encodes a protein 
required for the transport of thiamine pyrophosphate into mitochondria. Children 
affected by this condition have a head circumference of up to 12 standard 
deviations less than the general population, elevated levels of 2-ketoglutarate 
within the urine and early neonatal death. Further research into microcephaly 
identified a mutation within the sodium-dependent lysophosphatidylcholine 
transporter MFSD2A which caused a non-lethal microcephaly syndrome within a 
large Pakistani family (Alakbarzade et al. 2015). 
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The investigation of inherited forms of microcephaly has enabled the identification 
of many new genes important for normal brain development, which when 
perturbed may give rise to ID (Gund et al. 2016) (Vinkler et al. 2014) (Leshinsky-
Silver et al. 2017) (Ji et al. 2015) (Tanaka et al. 2015). 
 
 
1.5 The Role of Community-Based Programs to Define Genetic Causes 
of ID 
Within clinical genetics, a marriage is traditionally considered as consanguineous 
when the two individuals are related as second cousins or closer (the inbreeding 
coefficient of their offspring is F ≥ 0.0156) (Bittles 2001), although over more 
recent years the term has been used to refer to marriages between individuals 
descended from the same ancestor. Occurrence of rare recessive syndromes, 
such as ID, has been shown to increase within consanguineous families (Teeuw 
et al. 2014). This is due to the higher chance of homozygosity for genetic variants 
carried by both parents, which in turn leads to the increased likelihood of 
recessive disorders occurring due to homozygosity for ‘founder’ gene mutations. 
 
 
Over recent years, genetic studies have been successful in identifying a number 
of new inherited disorders, in particular genetically isolated populations such as 
the Amish community. For example, the Windows of Hope Project (WoH) is a UK 
(Exeter)-led translational research program working in close partnership with 
clinical workers in the USA who care for families within the Anabaptist 
communities across North America. The program aims to define the genetic basis 
of inherited disorders that occur in the community, with a particular (but not 
exclusive) focus on ID, to aid disease diagnosis and clinical care locally while 
improving  medical-scientific  knowledge  of  human  inherited  disease. Results 
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obtained from this program alone have enabled the clinical characterisation of 20 
new inherited disorders. 
 
 
One example of the work conducted by WoH involves a form of ID involving 
macrocephaly (a term used to describe a head circumference of more than two 
standard deviations above average for their age), neurodevelopmental delay and 
seizures due to two distinct founder mutations, both present in the Amish 
community, in the gene that encodes kaptin (KPTN) (Baple, Maroofian, et al. 
2014). The importance of this finding to families is highlighted by the recent 
identification of numerous non- Amish families with the condition, stemming from 
the inclusion of the KPTN gene in gene sequencing diagnostic panels worldwide. 
Despite being published only recently, numerous clinicians have contacted the 
WoH research group for advice about the condition, for families harbouring the 
Amish mutations identified, as well as other candidate mutations in KPTN 
(Pajusalu, Reimand, and Ounap 2015). Taken together, this research not only 
highlighted kaptin as a molecule important for human neuromorphogenesis, but 
also highlighted the benefits of early diagnosis leading to improved clinical 
outcomes for patients worldwide with this disorder. 
 
 
In another example of WoH studies, a homozygous missense sequence 
alteration of PCNA (proliferating cellular nuclear antigen), a cofactor that 
orchestrates genome duplication and maintenance, was identified within the 
Amish community of Ohio (Baple, Chambers, et al. 2014). A principal feature of 
this novel syndrome was neurodegeneration, and the condition shares clinical 
and molecular features common with other DNA repair conditions. Defining the 
molecular basis of the disease has provided a better understanding of the 
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These and other similar studies highlight the importance of investigating the 
biological basis of rare diseases which have a direct impact on the wider 
population, as increased knowledge into gene function can help aid investigations 




This thesis derives from studies that form part of the University of Exeter 
Community Genetics Group translational genomic medicine program to aid 
genetic diagnosis and clinical care in families with inherited neurodevelopmental 
disorders. The families that are included in this thesis are all from the Nablus 
region of the West Bank, an area that has been, and continues to be, a place of 
conflict between Israel and Palestine (Gelvin 2014). The history of Israel and 
Palestine is a long and complex one, which has led to a unique genetic 
demographic within the area. The years of conflict and migration have created 
certain historical population bottlenecks (Kacowicz and Lutomski 2007), 
contributing to the occurrence of specific gene pools throughout this region. This 




A ‘population bottleneck’ occurs when a population becomes notably smaller very 
quickly. This can be due to migration/emigration patterns, a natural disaster, 
disease, war or other events. The sudden decrease in population size limits the 
amount of genetic variation within the population, which may lead to previously 
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rare ‘founder’ alleles becoming more common (the founder effect), once the 
population size recovers. The Amish community exemplifies how the founder 
effect has led to important repercussions for medical care based on the increased 
occurrence of otherwise rare inherited disorders within the community, although 
it is important to note that certain disorders that are common in other populations 
may occur at low frequency or even be absent in the Amish. Similarly, the high 
rate of consanguinity and specific marriage patterns within Middle Eastern 
societies has also led to increased frequencies of certain otherwise rare recessive 
disorders (Zlotogora 1997; Khalailah A et al. 2018). Due to the history of the 
Nablus population, it is likely that a number of the genetic mutations found within 





This research study stems from an ongoing collaborative translational genomic 
medicine program between researchers in Exeter and clinicians in Nablus to aid 
diagnosis of families with intellectual disability. Four families with individuals who 
have complex intellectual disability disorders have been identified through the 
program. The aim of this research was to identify known and potentially new 
candidate genes and genetic variants to define the genetic causes of intellectual 
disability amongst these families. 
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SUBJECTS AND METHODS 
 
As part of an ongoing collaboration between clinicians in Nablus (Israel) and the 
University of Exeter (UK), multiple families were identified with varying clinical 
phenotypes of undiagnosed neurodevelopmental disorders.  Blood samples were 
collected with informed consent by the Israeli clinician and sent to the University 
of Exeter for genetic investigations. A genetic testing strategy was employed to 
determine the genetic basis of these conditions, which involved a combination of 
genome-wide single nucleotide polymorphism (SNP) genotyping and whole 
exome sequencing (WES).  
 
 
2.1 Single nucleotide polymorphism (SNP) genotyping 
 
SNP microarray genotyping was performed by Dr. Barry Chioza, University of 




2.2 Primer Design 
 
The UCSC Genome Browser (GRCh37/hg19 Feb 2009 assembly) was used to 
acquire the nucleotide base sequences of the genes of interest (website 
https://genome.ucsc.edu/index.html). Primers for PCR amplification were 




The criteria used for primer selection was as followed: 
 
 
1. Primer sizes were between 20-30 bases in length, to ensure binding 
specificity and annealing temperatures were accurate. 
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2. Melting temperatures of both flanking primers were kept as similar as 
possible (between 56- 61°C), to maintain PCR optimization and efficiency. 
 
 




4. Primers with inter or intra-primer efficiency extending for more than 3 




5. Primers were specific and matched 100% with the target region. This was 
checked by using in silico PCR analysis and BLAST searches using the 
UCSC Genome Browser website. 
 
 
2.3 Polymerase Chain Reaction (PCR) 
 
PCR is an in vitro method of amplifying targeted lengths of DNA exponentially. 
Each PCR reaction undergoes a number of cycles consisting of three stages: 
denaturation, primer annealing and DNA synthesis. PCR increases the DNA 
concentration of a sample to enable purified PCR products to then be sequenced. 
 
 
For each PCR, a master mix containing all listed components (except DNA) was 
created (Table 2-1). A DNA control was used to ensure PCR efficiency, as well 
as a negative control of ddH2O to ensure that the desired DNA template was 
being amplified, and not a contaminant. 9.2 µl of master mix was then aliquoted 
into individual 0.2 ml Eppendorf tubes. 0.8 µl of the DNA sample/control or ddH2O 
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was added into sample, control and negative control tubes. A standard protocol 
of DNA amplification was followed. 
 
Table 2-1 Components of standard 10 μl PCR tube 
 
Component Volume (μl) 
Forward Primer (Sigma) 0.4 
Reverse Primer (Sigma) 0.4 
dNTPs (10mM) 0.4 
Dream Taq Green Buffer 1.0 
Molecular grade ddH2O 6.9 
Dream Taq DNA Polymerase 0.1 
DNA sample, control or ddH2O 0.8 
 




2.4 Primer optimisation 
 
A gradient PCR program, running from 55-67°C was used to elicit the optimum 
temperature for primer pair annealing. 
 
 
2.5 Agarose gel electrophoresis 
 
Agarose gel electrophoresis is a method of visualising whether the desired DNA 
regions have been amplified. Agarose gel electrophoresis works by separating 
PCR products by their molecular size, therefore indicating the size of the PCR 
product. 
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1.7g agarose powder was added to 100ml 1x LAB buffer to make a 1.7% agarose 




Table 2-2. 50x LAB buffer solution composition 
 
51g Lithium acetate dehydrate 
31g Boric acid 
Make up to 1L with dH20 
 
 
The powder and buffer mixture was heated in a microwave on high heat until all 
powder had dissolved and the mixture was clear. 5µl of 10mg/ml ethidium 
bromide was carefully pipetted into the agarose solution, which was then poured 
into a casting tray with combs in place to make wells. Ethidium bromide is a DNA 
intercalating agent that fluoresces brightly when exposed to ultraviolet light, 
making the DNA bands easy to visualise. 
 
 
Once set, the combs were removed and the gel placed within an electrophoresis 
tank containing enough 1x LAB buffer to submerge the gel. 5µl of 1kb plus ladder 
from Invitrogen was pipetted into a well, and 2µl of PCR product loaded into each 
subsequent well. The gel was left to run for at least 25 minutes at 150 volts, and 
then visualised under a UV transilluminator and photographs taken. If the 
negative control showed a DNA band, PCR products were discarded and PCR 
attempted again. 
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2.6 EXOSAP Purification of PCR product 
 
Prior to sequencing it was necessary to remove unincorporated primers and 
dNTP’s. This was done using EXOSAP, a product that contains Exonuclease-I 
(EXO) and Shrimp Alkaline Phosphatase (SAP). EXO degrades single stranded 
DNA in a 3’ to 5’ direction, releasing deoxyribonucleoside 5 prime- 
monophosphates. This releases dNTPs from the unincorporated primers. SAP 
catalyses the release of 5’ and 3’ phosphate groups from left over nucleotides. 
2μl of EXOSAP was added to 5μl of each PCR sample product. The samples 
were then placed back into the thermal cycler and the EXOSAP program run. 
This program incubates the samples at 37°C for 15mins (the optimal temperature 
for the enzyme activity) and then denatures the enzyme by heating the samples 
to 85°C for 15mins. 
 
 
2.7 DNA Sequencing 
 
Purified PCR products with 5 of forward primer per sample were then sent to 
Source Bioscience Lifesciences, Cambridge, UK for dideoxy DNA sequencing. 
Whole genome exome (WES) analysis (NextSeq500: Illumina) involved: Agilent 
Sureselect Whole Exome v6 for targeting, with read alignment with BWA-MEM 
(v0.7.12), mate-pairs fixed and duplicate removal (Picard v1.129), InDel 
realignment / base quality recalibration (GATK v3.4-46), SNV/ InDel detection 
(GATK HaplotypeCaller and annotation (Alamut v1.4.4) and read depth (GATK 
DepthOfCoverage) to provide files (Excel) comprising all genetic variants 








Genome-wide SNP mapping and exome sequencing were used to identify 
putative copy number variants (CNVs), as well as candidate genomic regions of 
interest assuming initially autozygosity for putative founder mutations, although 
also considering other genetic causes. 
 
 
3.1 Sequence alteration of ALG1 associated with a congenital disorder 
of glycosylation 
 




Family 1 (Figure 3-1) includes 3 affected individuals presenting with ID, learning 
difficulties, hyperactivity, low attention span, speech delay, lower limb spasticity, 
mild hearing loss and non-dysmorphic microcephaly at -2SD. 
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Genome-wide SNP mapping was undertaken using DNA from all affected 
siblings. In order to identify CNV’s, all affected individuals underwent whole 
genome microarray scan using Illumina Human CytoSNP-12v2.0 and 2.1 arrays. 
Data analysis was performed using karyostudio and genomestudio software 
(Illumina) to identify CNVs shared between affected individuals. No CNV’s were 
identified, however regions of autozygosity common to all affected individuals 


































Figure 3-2. Visual depiction of largest autozygous regions of the genome (shown in red) common to all 
three affected siblings in Family 1 
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Table 3-1 Largest regions of autozygosity common to affected members 
in Family 2 
 
 
Cross referencing the largest region of autozygosity on chromosome 16 with the 
SysID Database (Website: https://sysid.cmbi.umcn.nl/), 14 candidate or primary 
ID genes were identified to be located within this region (Table 3-2). 
 
 
Whole exome sequencing of VI:3 was used to identify rare or novel candidate 
gene variants within regions of autozygosity, as well as genome-wide. The data 
was filtered to an allele frequency of <0.005% (with an initial frequency of <0.01% 
considered) to identify rare variants. Frameshift, nonsense, missense and 
essential splice site variants were all included in the filtering process to identify 
potentially deleterious variants. Those without any data available for their SIFT 
or POLYPHEN predictions of severity, or without a published allele frequency, 
were included in the shortlisting. Genes for which an individual was reported in 
homozygous state on gnomAD were excluded (website: 
http://gnomad.broadinstitute.org), to leave initially only a very selective list of 
variants. The genomic location of each gene was cross-referenced with the 
genome-wide SNP data, to identify the putative genotypings of each affected 
family member (indicated in table 3-3; ‘haplotype region’ column in which “All 
33  
three” indicates a SNP haplotype across each gene common to all three affected 
family members). 
 
Table 3-2 Candidate/ Primary ID genes identified within the largest region 
of autozygosity from SysID for Family 1. 
 
 
Whole exome sequencing identified only a limited number of candidate sequence 
variants (Table 3-3). Most notably, this included a homozygous variant within a 
gene located in the chromosome 16 region of homozygosity; ALG1 (highlighted 
through SysID) (Table 3-2, Table 3-3). The variant identified within ALG1 has 
previously been reported to be one of a number of ALG1 mutations associated 
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with a rare autosomal recessive disorder termed ALG1- CDG (Ng et al.  
 
 
Individuals with ALG1-CDG present with a neurological disorder characterised by 
neurodevelopmental delay, hypotonia, microcephaly and varying dysmorphic 
facial features. These features display significant overlap with the clinical 
characteristics of the affected individuals within family 1. Thus while the role of 
the other sequence variants identified in C16orf89, CACNA1H, CASKIN1, and 
PKD1 remains unclear, the ALG1 variant seems most likely to represent the 
genetic cause of the condition in Family 1. 
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Table 3-3 Novel and rare homozygous variants identified from whole exome sequencing of VI:3 
 
Gene Name ID cNomen pNomen SIFT Known Phenotype Haplotype region 
ALG1 rs151173406 NM_019109.4:c.826C>T p.Arg276Trp Deleterious Congenital Disorders of Glycosylation All three 
C16orf89 rs371481724 NM_152459.4:c.514G>T p.Asp172Tyr Deleterious  All three 
CACNA1H rs61018135 NM_021098.2:c.2069C>T p.Ala690Val Tolerated Familial Hyperaldosteronism Type IV All three 
CASKIN1 . NM_020764.3:c.2525G>A p.Gly842Asp Deleterious  All three 
PKD1 rs144512402 NM_001009944.2:c.3947A>T p.Tyr1316Phe Tolerated Polycystic kidney disease All three 
PKD1 . NM_001009944.2:c.3695G>C p.Ser1232Thr Tolerated Polycystic kidney disease All three 
GLI2 rs150170739 NM_005270.4:c.1418G>A p.Arg473His Deleterious Culler-Jones syndrome and Holoprosencephaly 9 VI:2 and VI:3 
LRRC31 rs187788865 NM_001277128.1:c.1370C>T p.Pro457Leu Deleterious  VI:2 and VI:3 
LRTOMT rs138915488 NM_001318803.1:c.529C>T p.Arg177Cys Tolerated Deafness VI:2 and VI:3 
SYNE1 rs373935459 NM_182961.2:c.23314C>T p.Arg7772Trp Deleterious Emery-Dreifuss muscular dystrophy-4 VI:2 and VI:3 
ATP2A2 rs140234740 NM_170665.3:c.3064A>G p.Ile1022Val Tolerated Darier-White disease VI:3 
COL7A1 rs146783561 NM_000094.3:c.2666C>T p.Pro889Leu Tolerated Epidermolysis bullosa dystrophica VI:3 
MYO7A . NM_000260.3:c.2467C>T p.Arg823Cys Tolerated Usher syndrome type 1B and Deafness VI:3 
MYO7B rs373648776 NM_001080527.1:c.5080G>A p.Asp1694Asn Deleterious  VI:3 
NARS2 rs146900529 NM_024678.5:c.844G>A p.Ala282Thr Tolerated Combined oxidative phosphorylation deficiency 24 VI:3 
PNRC1 . NM_006813.2:c.211C>A p.Gln71Lys Tolerated  VI:3 
PTRHD1 . NM_001013663.1:c.196C>T p.Pro66Ser Tolerated  VI:3 
ABCB11 . NM_003742.2:c.2238A>T p.Lys746Asn Tolerated Cholestasis VI:3 
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Primers were designed to amplify the ALG1 gene variant (See Appendix 7.1) to 
validate the presence of the variant, and confirm cosegregation. As expected 
from the SNP haplotype data, the three affected siblings (VI:1, VI:2 and VI:3) 
were all homozygous for the c.826C>T variant. To ascertain if this variant 
cosegregated within the wider family, the parents (V:3 and V:4) and the 
unaffected sister (VI:4) were also sequenced. This confirmed that the parents 
were both heterozygous carriers for the mutation, as is the unaffected sister 
(Figure 3-3).  
 
Figure 3-3 Sequencing chromatogram from a parental heterozygous carrier for the ALG1 c.826C>T gene 









3.2 Defining mutations within an ARHGAP molecule as a likely new 



































Family 2 comprises an extended family involving 2 affected individuals present in 
two nuclear families (Figure 3-4). Both affected individuals are females 
presenting with global developmental delay, absent-speech, a failure to thrive, 
axial hypotonia, peripheral spasticity, are bed-ridden, and have microcephaly of 
up to -3SD. Both also have dysmorphic features including prominent ears, cleft 
soft palate and left cupped ear. 
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Assuming that a founder mutation is responsible, genome-wide SNP mapping of 
both the affected individuals was undertaken alongside whole exome sequencing 
of individual VI:1, as described in family 1. SNP mapping identified no CNV’s, 
however two regions of autozygosity on chromosome 19 and 7 were identified 


































Figure 3-5. Visual depiction of largest autozygous regions of the genome (shown in red) common to 
affected siblings in Family 2 
 
 
Table 3-4 Largest regions of autozygosity common to affected members 
in Family 2 
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Whole exome sequencing was filtered to identify novel/rare (allele frequency 
 
<0.005%) deleterious homozygous variants, initially prioritising the largest region 
of autozygosity on chromosome 19, although also considering homozygous and 
compound heterozygous candidate variants genome-wide (Table 3-5). 
(Haplotype region column “Both homozygous” indicates a SNP haplotype across 
each gene common to the two affected family members.) This identified 8 
candidate variants, with only one in ARHGAP being predicted deleterious by SIFT 
and PolyPhen. Notably, examination of the literature involving each gene 
identified highlighted a candidate variant within the same ARHGAP gene 
implicated as a candidate genetic cause of a neurodevelopmental disorder (See 
discussion section 4). 
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Table 3-5. Novel and rare homozygous variants identified from whole exome sequencing of VI:1 
 
Gene Name ID c.Nomen p.Nomen SIFT prediction Known Phenotype SNP Region 
ARHGAP . c.1673C>T p.Ser558Phe Deleterious Identified as candidate gene for intellectual disability. both homozygous 
FDFT1 rs71711801 NM_001287750.1:c.226_231del p.His76_Ser77del   both homozygous 
HNRNPL . NM_001533.2:c.604C>T p.Pro202Ser Tolerated  both homozygous 
PDCD2L . NM_032346.1:c.449C>A p.Ala150Asp Tolerated  both homozygous 
PTGIR . NM_000960.3:c.268G>A p.Ala90Thr Tolerated  both homozygous 
SARS2 . NM_017827.3:c.422G>A p.Arg141His Tolerated HUPRA syndrome both homozygous 
ZNF181 rs370173129 NM_001029997.3:c.407A>C p.Asp136Ala Tolerated  both homozygous 
ZNF781 . NM_152605.3:c.444G>C p.Gln148His Tolerated  both homozygous 
AGTPBP1 . NM_001286715.1:c.42_47dup p.Ala18_Ala19dup   not shared 
AKAP2 . NM_001136562.2:c.2396A>G p.Gln799Arg Tolerated  not shared 
AKAP2 . NM_001198656.1:c.2663A>G p.Gln888Arg Tolerated  not shared 
AKNA . NM_001317952.1:c.2923A>T p.Ser975Cys Deleterious  not shared 
AKNA . NM_030767.5:c.3280A>T p.Ser1094Cys Deleterious  not shared 
AKNAD1 rs141526254 NM_152763.4:c.961G>C p.Gly321Arg Tolerated  not shared 
AP2A2 . NM_001242837.1:c.2657C>T p.Pro886Leu Deleterious  not shared 
ARHGAP45 . NM_012292.4:c.1534A>G p.Met512Val   not shared 
ASPN rs111419727 NM_017680.4:c.150_152dup p.Asp50dup  D14 allele associated with Osteoarthritis not shared 
CCDC114 . NM_144577.3:c.448A>T p.Arg150Trp Deleterious Ciliary dyskinesia not shared 
CCDC177 rs147747237 NM_001271507.1:c.531_536del p.Ala179_Ala180del   not shared 
CTSD . NM_001909.4:c.190G>A p.Glu64Lys Tolerated Neuronal ceroid lipofuscinosis not shared 
EP400 . NM_015409.4:c.7410C>A p.Asp2470Glu Deleterious  not shared 
EP400 . NM_015409.4:c.8223_8225dup p.Gln2748dup   not shared 
GDF7 . NM_182828.3:c.141_149dup p.Gly48_Gly50dup   not shared 
IFITM10 . NM_001170820.3:c.541C>T p.Arg181*   not shared 
KRTAP5-6 . NM_001012416.1:c.251G>T p.Gly84Val Deleterious  not shared 
KRTAP9-1 rs11283848 NM_001190460.1:c.483_484ins27 p.Pro161_Cys162ins9   not shared 
NDUFS7 rs201112782 NM_024407.4:c.31G>A p.Gly11Ser Tolerated Leigh syndrome not shared 
NPIPB6 rs2411937 NM_001282524.1:c.917C>T p.Ala306Val Tolerated  not shared 
PALM2-AKAP2 . NM_007203.4:c.3089A>G p.Gln1030Arg Deleterious  not shared 
PCDHA10 . NM_018901.3:c.476C>A p.Ala159Glu Tolerated  not shared 
PHOX2B rs17879189 NM_003924.3:c.756_776del p.Ala254_Ala260del  Central hypoventilation syndrome and Neuroblastoma susceptibility not shared 
RNF212 rs138488801 NM_001193318.2:c.721_722ins21 p.Ser241delins8   not shared 
RPS6KA2 rs201444480 NM_021135.5:c.1237G>A p.Asp413Asn Tolerated  not shared 
RSF1 . NM_016578.3:c.2350C>A p.Pro784Thr Tolerated  not shared 
SLC10A2 . NM_000452.2:c.162_203dup p.Ile55_Ile68dup   not shared 
SLC3A2 . NM_001012662.2:c.70T>C p.Ser24Pro Tolerated  not shared 
SPATA31A3 . NM_001083124.1:c.3943G>T p.Val1315Leu Tolerated  not shared 
TENM3 . NM_001080477.3:c.5223G>C p.Glu1741Asp Tolerated Microphthalmia not shared 
USP20 . NM_001008563.4:c.2101G>A p.Ala701Thr Tolerated  not shared 
ZFP42 rs148426653 NM_174900.4:c.89G>A p.Gly30Asp Tolerated  not shared 
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Primers were designed to amplify and validate the ARHGAP gene variant, and 
confirm cosegregation. As expected the two affected girls (V:1 and VI:1) both 
harboured the same c.1673C>T/ p.Ser558Phe variant in homozygous form. To 
ascertain if this variant cosegregated within the wider family, both sets of parents 
(IV:1+IV:2 and V:4+V:5) and the two unaffected brothers (VI:3 and VI:2) were 
also sequenced, confirming that the parents were both heterozygous carriers for 




Figure 3-6 Sequencing chromatograms for ARHGAP 
c.1673C>T gene variant 
 
To check whether any of the other Nablus families may also harbour the 
ARHGAP mutation, a single affected individual from each family was also 
sequenced for the ARHGAP variant. All were wildtype. 
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3.3 Exome sequencing identifies new candidate genetic causes of ID in 
an extended family with individuals with this disorder 
Figure 3-7 Family 3 pedigree 
 
Family 3 includes 4 affected individuals (including a pair of monozygotic twins; 
Figure 3-7), presenting with intellectual disability, speech disturbances, delayed 
gross motor skills, short stature, dysmorphic features and generalized seizure 
disorder, which are controlled by antiepileptic drugs. 
 
 
Genome-wide SNP mapping was undertaken using DNA from the three affected 
brothers (IV:1, IV:2, IV:3). A possible micro-duplication, common to all three 
brothers was identified on chromosome 17 (Figure 3-8). Four regions of 
autozygosity common to all three were also identified; two large regions within 
chromosome 16, as well as two smaller regions on chromosomes 1 and 13 
(Figure 3-9, Table 3-6). 
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Figure 3-9 Karyotyping of three affected individuals within Family 3 to identify shared CNV's (highlighted 
by red box) 
 
Figure 3-8 Visual depiction of largest autozygous regions of the genome (shown in red) common to all 
three affected siblings in Family 3 
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Table 3-6 Largest regions of autozygosity common to affected members 




The duplication region within 17q21.31 contains one gene (KANSL1), however 
further research into this duplication is required as the SNP data cannot confirm 
conclusively that this duplication is genuine. Duplications within 17q21.31 have 
been reported within a handful of intellectual disability patients with the term 
17q21.31 micro-duplication syndrome now being used. 
 
 
To identify any candidate sequence variants in genes of interest within the 
regions of autozygosity, the largest region was cross-referenced with the SysID 
database (Website: https://sysid.cmbi.umcn.nl/), which identified 15 candidate 
primary ID genes (Table 3-7). 
 
 
Whole exome sequencing of VI:1 was used to identify rare (<0.005%) or novel 
candidate gene variants within the regions of autozygosity, as well as genome- 
wide (Table 3-8). The data was filtered as described previously (Section 3.1). 
(Tables 3-8 and 3-9 haplotype region column “All three” indicates a SNP 
haplotype across each gene common to all three affected family members.) No 
candidate homozygous variants were found within any of the ID genes identified 
by SysID within the largest region of autozygosity, however 7 homozygous 
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variants were identified genome wide. The exome data was also inspected for 
candidate compound heterozygous variants (Table 3-9). Any variant identified in 
homozygous form as per gnomeAD Browser (website: 
http://gnomad.broadinstitute.org) were discarded from the initial analysis as 
potential candidate variants. This identified a number of sequence variants likely 
present in homozygous (or compound heterozygous) state in all three affected 
siblings, with one gene known to cause autosomal dominant mental retardation 
(Table 3-8). As a number of novel candidate variants were identified, further work 
including the genotyping of additional family members (once samples become 
available) may identify a new genetic cause of this condition. 
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Table 3-7 Candidate/ Primary ID genes identified within the largest 




Table 3-8 Novel and rare homozygous variants identified from whole exome sequencing of VI:1 
 
Gene Name ID cNomen pNomen SIFT Known Phenotype Haplotype Region 
DHX38 . NM_014003.3:c.889C>T p.Arg297Cys Deleterious Possible role in retinitis pigmentosa All three 
KIAA0355 . NM_014686.3:c.1585T>G p.Ser529Ala Deleterious  All three 
SALL3 . NM_171999.3:c.545C>G p.Ser182Trp Deleterious  All three 
MYLPF rs201552895 NM_001324458.1:c.350A>G p.Lys117Arg Tolerated  All three 
NUP93 . NM_014669.4:c.1348G>A p.Glu450Lys Tolerated Nephrotic syndrome All three 
ZNF681 . NM_138286.2:c.1081A>G p.Thr361Ala Tolerated  All three 
BEAN1 . NM_001178020.2:c.307T>C p.Tyr103His Tolerated Spinocerebellar ataxia All three 
BAG3 . NM_004281.3:c.557C>T p.Ala186Val Tolerated Cardiomyopathy VI:1 and VI:2 
NOMO3 . NM_001004067.3:c.2161A>G p.Arg721Gly Deleterious  VI:1 and VI:2 
DNAH3 rs200671634 NM_017539.2:c.3070A>G p.Lys1024Glu Tolerated  VI:1 and VI:2 
ZNF99 rs183240953 NM_001080409.2:c.419C>T p.Thr140Ile Tolerated  VI:1 and VI:2 
ZNF91 rs372751233 ENST00000397082.2:c.2047A>G p.Lys683Glu Tolerated  VI:1 and VI:2 
DCLK2 . NM_001040261.4:c.106A>G p.Ser36Gly Tolerated  VI:1 and VI:2 
 
Table 3-9 Novel and rare compound heterozygous variants identified from whole exome sequencing of VI:1 
 
Gene Name ID cNomen pNomen SIFTprediction Known Phenotype Haplotype Region 
MYT1L . NM_001303052.1:c.869C>T p.Ser290Leu Tolerated Mental retardation All three 
MYT1L . NM_001303052.1:c.373G>A p.Glu125Lys Tolerated Mental retardation All three 
RGPD4 . NM_182588.2:c.80C>T p.Thr27Met Tolerated  All three 
RGPD4 . NM_182588.2:c.3982G>C p.Glu1328Gln Deleterious  All three 
AMER3 rs201307390 NM_152698.2:c.538G>A p.Glu180Lys Tolerated  All three 
AMER3 rs200166860 NM_152698.2:c.1033G>T p.Ala345Ser Tolerated  All three 
ZNF717 rs199663998 NM_001128223.2:c.856G>A p.Val286Ile Tolerated  All three 
ZNF717 rs200828229 NM_001128223.2:c.848A>G p.Tyr283Cys Tolerated  All three 
CPZ rs143281934 NM_003652.3:c.602G>A p.Ser201Asn Deleterious  All three 
CPZ rs139569426 NM_003652.3:c.1166A>T p.Lys389Met Deleterious  All three 
CYP4V2 rs202204817 NM_207352.3:c.1372G>A p.Val458Met Deleterious Bietti crystalline corneoretinal dystrophy All three 
CYP4V2 rs142244984 NM_207352.3:c.1493A>C p.Glu498Ala Deleterious Bietti crystalline corneoretinal dystrophy All three 
TAS2R19 rs370558279 NM_176888.2:c.535G>A p.Val179Ile Tolerated  All three 
TAS2R19 . NM_176888.2:c.529T>A p.Leu177Met Tolerated  All three 
TAS2R19 rs200043527 NM_176888.2:c.527G>A p.Ser176Asn Tolerated  All three 
NBPF1 . ENST00000430580.2:c.3200T>C p.Val1067Ala Tolerated  VI:1 and VI:2 
NBPF1 . ENST00000430580.2:c.1174C>T p.Arg392Cys Tolerated  VI:1 and VI:2 
HRNR rs113263380 NM_001009931.2:c.7570G>A p.Gly2524Ser Tolerated  VI:1 and VI:2 
HRNR . NM_001009931.2:c.7397G>A p.Arg2466His Tolerated  VI:1 and VI:2 
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Gene Name ID cNomen pNomen SIFTprediction Known Phenotype Haplotype Region 
FCRLA rs144403707 NM_032738.3:c.523G>A p.Ala175Thr Deleterious  VI:1 and VI:2 
FCRLA rs144830049 NM_032738.3:c.524C>A p.Ala175Glu Deleterious  VI:1 and VI:2 
SP8 rs185796187 NM_182700.5:c.487G>T p.Gly163Cys Deleterious  VI:1 and VI:2 
SP8 . NM_182700.5:c.475G>C p.Gly159Arg Deleterious  VI:1 and VI:2 
POMT1 rs142057517 NM_001077366.1:c.1090G>A p.Ala364Thr Tolerated Muscular dystrophy-dystroglycanopathy with mental retardation VI:1 and VI:2 
POMT1 rs138171526 NM_001077366.1:c.1898C>T p.Ala633Val Tolerated Muscular dystrophy-dystroglycanopathy with mental retardation VI:1 and VI:2 
DRD4 . NM_000797.3:c.860A>G p.Gln287Arg Tolerated Risk factor for ADHD VI:1 and VI:2 
DRD4 . NM_000797.3:c.863A>G p.Asp288Gly Tolerated Risk factor for ADHD VI:1 and VI:2 
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3.4 Further genetic studies are required to determine the cause of ID in 



































Family 4 incorporates multiple interlinking families with 7 affected individuals (in 
three nuclear pedigrees), one of whom is deceased (Figure 3-10). The siblings 
from the marriage between V:4 and V:5 were the research focus of this family. All 
three surviving siblings present with severe psychomotor retardation, speech 
delay, failure to thrive, can only crawl/ are wheelchair bound and have axial and 
peripheral hypotonia. All siblings have varying degrees of microcephaly, and 
sensorineural hearing loss. 
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Assuming that a founder mutation was most likely responsible for the condition, 
genome-wide SNP mapping was undertaken which identified one micro- 
duplication within one copy of chromosome 14 in all affected individuals (Figure 
3-11). This analysis also identified autozygous regions common to the affected 
individuals within chromosomes 7, 12 and 17 (Figure 3-12, Table 3-10). 
Figure 3-11 Karyotyping of three affected individuals within Family 4 to identify shared CNV's (highlighted 
by red box) 
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Figure 3-12 Visual depiction of largest autozygous regions of the genome (shown in red) common to 





Table 3-10. Largest regions of autozygosity common to affected members 
of Family 4 
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The duplication region within 14q21.2 contains only one pseudogene (KRT8P2) 
and may therefore be unlikely to be pathogenic. However, there is a patient 
reported within DECIPHER v9.24 (website: https://decipher.sanger.ac.uk/) who 
is also heterozygous for a duplication on chromosome 14 which overlaps the 
coordinates of the duplication found within Family 4. The individuals’ phenotype 
consists of microcephaly, facial abnormalities and intellectual disability. 
 
 
Whole exome sequencing was also undertaken of a single affected individual 
(VI:8) to identify rare (<0.005%) or novel candidate gene variants within the 
autozygous regions, as well as genome-wide (Table 3-11). The data was filtered 
as described above (Section 3.1) No candidate homozygous variants in genes 
located within the largest shared autozygous regions or genome wide were 
identified. Finally, the exome data was inspected to identify candidate compound 
heterozygous variants (Table 3-12). Any variant identified in homozygous form 
as per gnomeAD (website: http://gnomad.broadinstitute.org) were discarded as 
potential candidate variants and removed from the table. No candidate compound 
heterozygous variants were identified. 
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Table 3-11. Novel and rare homozygous variants identified from whole exome sequencing of VI:8 
 
Gene Name ID cNomen pNomen PolyPhen SIFT Known Phenotype Haplotype Region 
ANKRD36 . NM_001164315.1:c.959C>T p.Ser320Leu Damaging Tolerated  VI:8 
CARD6 rs143022216 NM_032587.3:c.1340T>C p.Leu447Pro Damaging Deleterious  VI:8+ VI:6 
CHL1 . NM_006614.3:c.3355G>T p.Val1119Leu Damaging Deleterious Candidate gene for an autosomal 
form of intellectual disability. 
VI:8 
ESPL1 . NM_012291.4:c.1154G>T p.Gly385Val Benign Tolerated  VI:8+ VI:7 
FDFT1 rs71711801 NM_001287750.1:c.226_231del p.His76_Ser77del    VI:8 
USP17L10 . NM_001256852.1:c.718T>A p.Leu240Met Damaging Tolerated  VI:8+ VI:6 
 
Table 3-12. Novel and rare compound heterozygous variants identified from whole exome sequencing of VI:8 
 
Gene Name ID cNomen pNomen SIFTprediction Known phenotype Haplotype region 
NBPF1 . ENST00000430580.2:c.1051_1053del p.Glu351del   VI:6+VI:7 
NBPF1 . ENST00000430580.2:c.2092C>A p.Gln698Lys Not scored  VI:6+VI:7 
OBSCN rs199738703 NM_052843.3:c.11750C>T p.Thr3917Ile Tolerated  VI:6+VI:7 
OBSCN rs200262505 NM_052843.3:c.15689C>T p.Thr5230Met Deleterious  VI:6+VI:7 
PCNT . NM_001315529.1:c.1589C>G p.Pro530Arg Tolerated Microcephalic osteodysplastic primordial 
dwarfism type II 
VI:6+VI:7 
PLB1 . NM_001170585.1:c.892A>T p.Thr298Ser Tolerated  VI:6+VI:7 
PLB1 . NM_153021.4:c.859A>T p.Thr287Ser Tolerated  VI:6+VI:7 
PLB1 . NM_153021.4:c.863C>A p.Thr288Asn Tolerated  VI:6+VI:7 
PLB1 . NM_153021.4:c.869C>A p.Ser290Tyr Tolerated  VI:6+VI:7 
PRSS3 . NM_007343.3:c.257C>A p.Thr86Asn Tolerated  VI:6+VI:7 
ALDH16A1 rs146615636 NM_153329.3:c.1484C>T p.Ser495Phe Tolerated Possible role in gout VI:8+VI:6 
DGKG . NM_001346.2:c.2152C>G p.Gln718Glu Deleterious  VI:8+VI:6 
DGKG . NM_001346.2:c.2149G>T p.Gly717Trp Deleterious  VI:8+VI:6 
FOXO6 rs373524987 ENST00000372591.1:c.1009_1010del p.Gln337Glyfs*39  Potentially role in neurodegenerative disorders 
and risk gene of bipolar 
VI:8+VI:6 
FOXO6 . ENST00000372591.1:c.1013C>G p.Ala338Gly Not scored  VI:8+VI:6 
ADAMTSL4 . NM_001288607.1:c.419T>A p.Ile140Asn Tolerated Ectopia lentis VI:8+VI:7 
ADAMTSL4 . NM_001288607.1:c.2372C>G p.Pro791Arg Deleterious  VI:8+VI:7 
DUOX1 rs367870737 NM_017434.4:c.2425G>A p.Glu809Lys Tolerated  VI:8+VI:7 
DUOX1 . NM_017434.4:c.3317G>A p.Arg1106His Deleterious  VI:8+VI:7 
FLG rs142483068 NM_002016.1:c.2363G>A p.Arg788Gln Not scored Ichthyosis vulgaris VI:8+VI:7 
GIGYF2 . NM_001103147.1:c.1889G>A p.Arg630Gln Tolerated Possible risk factor for Parkinson’s VI:8+VI:7 




Identifying candidate genes for neurodevelopmental disorders is important for the 
diagnostic process of the families, but also to help allude to the functions of genes 
of evolutionary importance for brain development and function. The research 
described in this thesis, through the collaboration between Exeter University and 
our Nablus colleagues, has enabled a suspected diagnosis to be provided for two 
families, and also identified a novel candidate disease gene responsible for ID. 
While two further families require further evaluations in order to reach diagnosis, 
these findings highlight the importance of such collaborative clinical-genetics 
programmes around the world. 
 
 
The first family investigated (Family 1, Section 3.1) includes 3 affected 
individuals, all with ID, learning difficulties, hyperactivity, low attention span, 
speech delay, lower limb spasticity, mild hearing loss and non-dysmorphic 
microcephaly at -2SD. Genome-wide SNP mapping identified no CNV’s, however 
chromosomes 2, 6, 12 and 16 all displayed regions of autozygosity common to 
all affected individuals. The largest region of autozygosity within chromosome 16 
contained 14 genes listed within the SysID database. Importantly, whole exome 
sequencing of VI:3 identified a rare (allele frequency 




Mutations within ALG1 are a well-documented cause of a rare autosomal 
recessive congenital disorder of glycosylation termed ALG1-CDG (Ng et al. 
2016). CDG’s are caused by defects in the synthesis and processing of 
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asparagine (ASN)-linked oligosaccharides of glycoproteins (Grunewald 2002). 
ALG1-CDG can be highly variable, but is usually characterised by; microcephaly, 
developmental delay, abnormal fat distribution, strabismus, and coagulation 
abnormalities (Morava. et al. 2012), with recurrent infantile seizures, cerebellar 
hypoplasia, hypotonia, and failure to thrive also being described in ALG1-CDG 
patients (Harshman et al. 2016).  
 
The c.826C>T variant identified within the family investigated here has previously 
been reported in compound heterozygous form with c.1263G>A mutation within 
a young male from France (Dupre et al. 2010) who presented with psychomotor 
delay, growth retardation, hypotonia, multi-focal epilepsy and facial dysmorphic 
features. While it is likely that the ALG1 alteration represents the cause of the 
condition in this family, there were some difficulties with obtaining pure 
sequencing chromatograms from the affected children. Resequencing using 
repositioned oligonucleotide primers will enable sequence verification and 
confirmation, thus reporting the first three cases of individuals with this variant in 
homozygous form. Abnormal isoelectric focussing of transferrins is seen in 
individuals with CDG disorders and this confirmatory clinical investigation is being 




Other homozygous variants were also identified within homozygous genomic 
regions shared between all three affected individuals, and therefore expected to 
be found in homozygous form. While these cannot be conclusively excluded, 
none of them are known to cause ID. Of these homozygous variants, only the 
variants within C16orf89 and CASKIN1 were predicted to be deleterious. The 
C16orf89 gene and protein shows little to no expression within the brain and has 
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no known corresponding phenotype, and may therefore be unlikely to be 
pathogenic. CASKIN1 however is very highly expressed within the brain, and the 
Gly842Asp variant is very rare with only two heterozygous carriers reported within 
gnomAD. It is currently unclear as to if or how this variant may contribute to the 
ID phenotype within the family. While the relevance of the other variants identified 
in family 1 remains unclear, together these findings identify the ALG1 mutation 
as the likely genetic cause of the condition in this family. This therefore likely 
provides an opportunity for genetic screening, as if the unaffected heterozygous 
sister decides to have children, it would be of importance to ascertain if her 
partner harbours a deleterious variant in this gene, as to establish the possible 
risk of them having children affected by this disorder, and be counselled 
accordingly. 
 
The second family investigated (Family 2, Section 3.2) comprised of two young 
females with microcephaly, dysmorphic features including prominent ears, cleft 
soft palate, left cupped ear, axial hypotonia and peripheral spasticity, as well as 
global developmental delay. Both girls are bed-ridden with absent speech and a 
failure to thrive. Genome-wide SNP mapping highlighted a notable region of 
autozygosity on chromosome 19 shared by the two affected children. Whole 
exome sequencing of this region identified a single variant within an ARHGAP 
gene (c.1673C>T), (specific gene identity withheld as requested by project 
sponsors Prof Crosby and Dr Baple) affecting a highly conserved serine at 
position 558 being replaced by phenylalanine (p.Ser558Phe). The variant is 
predicted to be deleterious in SIFT and POLYPHEN, and is listed at very low 
frequency (0.000007673) and not in homozygous form in the gnomAD browser 
across all populations. Both sets of parents of the affected children were 
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heterozygous for the mutation, and the unaffected brothers of VI:1 were wildtype 
(Figure 3-6), consistent with autosomal recessive inheritance for this founder 
mutation. 
 
A different variant within the ARHGAP gene was recently identified by a 
collaborator of the UEMS research group as a candidate cause of ID (Prof Crosby, 
personal communication). The variant is present in homozygous form in two 
siblings who displayed very similar clinical characteristics to the affected 
individuals in family 2, highlighting this gene variant as the likely cause of the 
disorder and confirming this gene as a likely new genetic cause of ID. Of the other 
homozygous variants identified from the exome data which lie within homozygous 
regions shared between the affected individuals, none represent obvious 
candidate genes. Only ZNF181 and ZNF781 are known to be expressed in the 
brain and these gene variants were not predicted to be deleterious by SIFT, 
although this alone does not exclude them.  
 
ARHGAP is highly expressed within the brain (Figure 4-1) and encodes a member 
of a unique subfamily of sorting nexins (SNX). Sorting nexins are a large family of 
proteins categorized by a conserved lipid-binding Phox (PX) domain, which have 
been shown to play critical roles within brain development (Nakazawa et al. 2011) 
(Mizutani et al. 2012) (Wang et al. 2013) (Muirhead and Dev 2014) (Mizutani et al. 
2011). The subfamily of sorting nexins in which ARHGAP belongs, contains the 









The Rho family of GTPases (Rho GTPases) is comprised of a number of small 
signalling G proteins, and are best known for their involvement within the 
reorganisation of the actin cytoskeleton and the orientation and stabilisation of 
microtubules, which is very important for correct neuronal development (Govek, 
Newey, and Van Aelst 2005). 
 
 
G proteins act as molecular switches, cycling between an active GTP bound state 
and inactive GDP bound state. The three key regulatory proteins involved in this 
cycling are guanine nucleotide exchange factors (GEFs), GTPase activating 
proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs). GEFs are 
proteins that facilitate the exchange of GDP for GTP, therefore promoting the 
active GTP-bound state. GAPs deactivate Rho GTPases by promoting the 
hydrolysis of GTP, and GDIs have recently been shown to play both a negative 
and positive role in the regulation of Rho activities (Dovas and Couchman 2005). 
The ARHGAP molecule identified is therefore expected to have a dual function 
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as both a sorting nexin and a deactivator of Rho GTPases. 
 
 
This ARHGAP molecule has also been shown to interact with other molecules 
linked to ID disorders, further indicating its potential role within ID pathogenesis 
(Figure 4-2). Variants within RAC1, RHOBTB2 and CDC42 and have all been 
described within patients with ranging ID phenotypes (Reijnders et al. 2017) 
(Straub et al. 2018) (Takenouchi et al. 2015). 
Figure 4-2 ARHGAP interaction as per STRING version 
10.5 
 
Further work needs to be conducted to discover just how the ARHGAP gene 
mutation may cause ID. Functional studies are currently ongoing within the UEMS 
research group and collaborators to validate this by investigating the outcomes 
of the sequence variants identified. This includes cell and protein binding partner 
studies, as well as studies of a mouse model of this gene. 
 
In the third family investigated (Family 3, Section 3.3), three affected brothers 
(one set of monozygotic twins) presented with intellectual disability, speech 
disturbances, delayed gross motor skills, short stature, dysmorphic features and 
generalised seizure disorder. Genome-wide microarray scanning identified a 
161kb micro-duplication within chromosome 17 which the three brothers shared. 
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Four regions of autozygosity within chromosomes 1, 13 and 16 were identified 
through genome-wide SNP mapping. 
 
 
Considering that approximately 60% of chromosome 16 was autozygous for the 
three affected individuals, and that a founder mutation was the likely cause of the 
disorder, it was expected that the pathogenic variant(s) would be found within 
chromosome 16. Surprisingly, inspection of the exome data of VI:1 revealed no 
candidate homozygous or compound heterozygous variants within the 
autozygous regions. No known candidate homozygous variants were found 
genome wide.  
 
Compound heterozygous variants within MYT1L were identified within a region 
on chromosome 2 in which the three affected individuals shared a haplotype. 
Neither of the two variants (p.Ser290Leu or p.Glu125Lys) have previously been 
reported. MYT1L has been identified as a candidate ID gene (de Ligt et al. 2012) 
with de novo heterozygous variants identified within a number of patients with 
autosomal dominant mental retardation (De Rocker et al. 2015) (Blanchet et al. 
2017). Given that the mode of inheritance of the disorder in family 3 is most likely 
recessive, it is unlikely that either MYTL1 variant is pathogenic. However, it may 
be possible that these two variants have less penetrance, and that when inherited 
together in compound heterozygous form a more severe ID phenotype is caused. 
It may also be possible that one (or both) of these variants are pathogenic, for 
which a parent is germline mosaic (although this is unlikely). Currently the 
collaborative Nablus team are recruiting additional family members to the study, 
including cousins, one of whom is also thought to be affected by the disorder 
(individual IV:7, Figure 3-7). Sequencing studies of these individuals will be very 
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helpful for elucidating which gene variant may be responsible for this condition. 
 
The 161kb duplication region within 17q21.31 contains one gene (KANSL1). 
Further research into this duplication is required (See Section 5) as the SNP data 
cannot confirm conclusively that this duplication is genuine and therefore cannot 
be considered a strong candidate for the pathogenic variant within this family yet. A 
deletion within KANSL1 is known to cause Koolen-De Vries syndrome (Zollino et 
al. 2012) (Koolen et al. 2012), which is an autosomal dominant ID syndrome 
(Koolen et al. 2006) (Koolen et al. 2008). Microduplications within 17q21.31 were 
first reported in 2007 by Kirchhoff et al and has since been termed 17q21.31 
microduplication syndrome (Kirchhoff et al. 2007). Since then only a handful of 
patients with 17q21.31 microduplication syndrome have been reported (Grisart et 
al. 2009) (Kitsiou-Tzeli et al. 2012) (Mc Cormack et al. 2014) (Natacci et al. 2016), 
all with intellectual disability and other characteristics such as microcephaly and 
behavioural abnormalities. Comparing the specific break points of the previously 
reported 17q21.31 microduplication syndrome cases and the approximate location 
of the duplication found within family 3, there is some overlap (Figure 4-3). The 
coding region of KANSL1 is from chr17:44,108,842-44,249,509. The first two 









Figure 4-3 Visual representation of the overlap between the reported 17q21.31 duplications and the 
duplication identified within Family 3. 
 
 
All of the previously reported duplications were either de novo or inherited in a 
dominant fashion both maternally and paternally. Although this may therefore 
discard 17q21.31 microduplication syndrome as the cause of the disorder within 
this family (as neither of the parents seem to be affected), it is important to note 
that 17q21.31 microduplication syndrome can show variable expressivity within 
the same family. It may therefore be possible that either of the parents may 
harbour the duplication but have a less severe phenotype. To explore this, further 
genetic studies could be carried out on all the affected individuals as well as 
unaffected siblings and parents to determine the exact break points of the 
duplication and determine if any unaffected individuals may also harbour the 
duplication. In the event that any of the “unaffected” individuals do have the 
duplication, more in depth clinical evaluations would be able to show if they have 
a milder phenotype and therefore either confirm the diagnosis or discard the 
duplication as a candidate for the disorder.  
 
Of the homozygous variants identified (Table 3-8) none of them are known to 
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cause ID. Three of the variants (within the genes DHX38, KIAA0355 and SALL3) 
were predicted deleterious by SIFT. Neither DHX38 or KIAA0355 are highly 
expressed within the brain, however SALL3 is (Figure 4-4). SALL3 is a zinc-finger 
protein and suspected transcription factor that has been shown to play a role in 
olfactory bulb dopaminergic neuron development by regulating tyrosine 
hydroxylase gene expression (Heng et al. 2012). This could therefore provide a 
possible mechanism by which a variant within this gene could result in an ID 
phenotype. Deletions and duplications within SALL3 have been reported within 
DECIPHER with patients with ID. There is no allele frequency information 
available for the p.Ser182Trp variant, so it can be assumed that it is incredibly 
rare. Within gnomAD two different variants at this position are reported in 
heterozygous form at very low frequency. The serine at position 182 is also highly 

























The other homozygous variants identified that were not predicted to be 
deleterious by SIFT do not appear to be strong candidates for ID. MYLPF and 
NUP93 show no expression within the brain and have no correlating ID 
phenotypes. Both ZNF681 and BEAN1 are expressed in the brain, however 
neither show a link to neurodevelopmental disorders. 
 
 
The fourth family under investigation (Family 4, Section 3.4) entails three 
individuals presenting with severe psychomotor retardation, speech delay, failure 
to thrive, axial and peripheral hypotonia as well as being either wheelchair bound 
or can only crawl. All siblings also have varying degrees of microcephaly, and 
sensorineural hearing loss. Genome-wide SNP mapping identified four modest 
sized autozygous regions shared by all affected individuals within chromosomes 
17, 7 and 12. Cross-referencing these autozygous regions with whole exome 
sequencing of one of the affected siblings failed to identify candidate homozygous 
variants within any of these regions, nor genome-wide. Candidate compound 
heterozygous were also not identified. The lack of definitive putative variants identified 
within this family, as well as in Family 3, may be due to methodological and technological 
limitations within this study. For example WES may not detect variants in regions in which 
there is low coverage. Additionally, the very nature of WES identifies sequence variants 
located within coding regions, so disease-causing variants located in non-coding regions 
(deep intronic, or intergenic regions) would not be identified. However our inability to (as 
yet) identify the causative variant(s) responsible for the disease in Family 4 may be due 
to other reasons.  
 
Due to the consanguinity within the family, the perhaps higher than expected 
number of affected individuals (3 of 5 siblings being affected), and the lack of 
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candidate genomic variants identified by whole exome sequencing, it may be 
possible that other more complex genetic mechanisms may underlie the condition 
in this family. One possibility may be that there is more than one inherited disorder 
cosegregating within the family. However this may be unlikely given the closely 
overlapping clinical features of the affected individuals in this family. Examination 
for shared autozygous regions between pairs of siblings/ affected individuals may 
help find candidate regions of interest, alongside more in-depth clinical evaluation 
of all the affected individuals to ascertain the likelihood of one or more disorders. 
Another possibility is that a more complex mode of inheritance may be at play. 
Germline mosaicism may be possible, which may explain why no candidate 
homozygous/compound heterozygous variations were identified. Mosaicism 
arises when an individual carries more than one set of genetic information. In 
germline mosaicism, the gamete DNA differs to that of the somatic cells. To 
investigate this, future genetic studies could be undertaken to identify candidate 
deleterious variants in genes known to cause autosomal dominant forms of ID. 
 
 
The SNP data identified a micro-duplication within 14q21.2 shared between the 
three siblings. This duplication is around 380kb in size and contains only one 
pseudogene (KRT8P2), so was assumed unlikely to be pathogenic. However, 
within DECIPHER v9.24 (website: https://decipher.sanger.ac.uk/), patient 
331321 is reported to be heterozygous for a duplication on chromosome 14 which 


















Figure 4-5 Chromosome 14 duplication location comparison between Family 4 and Patient 331321 
 
 
Patient 331321 has microcephaly, facial abnormalities and intellectual disability, 
a phenotype similar to the affected individuals within Family 4. The duplication 
within patient 331321 was reported as ‘likely pathogenic’ by DECIPHER, and 
therefore requires further evidence to be conclusive. It was also reported that 
patient 331321 inherited the duplication maternally, yet the mother was reported 
to have no clinical signs of a disorder. 
 
 
Chromosome 14 is known to be subjected to imprinting, with uniparental disomy 
(UPD) being reported on chromosome 14 (Kotzot and Utermann 2005) . Recently 
a duplication within 14q was reported in a patient born to a consanguineous 
marriage, in which the patient had mental retardation, growth retardation, 
dysmorphic features and muscle weakness (Sadr-Nabavi and Saeidi 2014). The 
exact duplication region of chromosome 14q was not specified, however it is likely 
that this duplication spanned a region containing important imprinting genes, 
such as the 14q32.2 imprinted region responsible for both maternal and paternal 
UPD-14 (Sutton and Shaffer 2000), which would therefore explain its pathogenic 
outcome. As the duplication region identified within this family doesn’t span any 




After highlighting potential candidate gene variants for ID, functional and cell 
studies are required to determine how any candidate mutations may affect protein 
structure and/or gene interactions resulting in the ID phenotypes described. Cell 
studies examining the functional effects of the ARHGAP variant identified through 
this work, as well as the previously reported variant, have begun at UEMS and 
with collaborative workers internationally. In particular mouse model studies 
aiming to introduce both the ARHGAP gene variant identified in family 2 as well 
as the distinct gene variant identified in our collaborator’s family into the knock 
out mouse model, will provide insight into the phenotypical and molecular 
outcomes of each gene mutation. 
 
 
Regarding families 3 and 4, in which no obvious variants within known ID genes 
were observed, recruitment of additional affected family members would enable 
most of the candidate variants to be excluded, and hopefully lead to the 
identification of a single primary candidate variant. In addition, it would be helpful 
to validate the presence of the possible duplications and specify the break points 
of the duplication regions proving them to be genuine and show whether or not 
they are present in unaffected members. To further ascertain if coding exons 
within genes located in the duplicate regions are disrupted, multiplex ligation- 
dependent probe amplification (MLPA) would confirm whether or not any exons 
are also duplicated. 
 
 
Identifying the precise molecular cause of disease in a family is invaluable for the 
clinical care of the individual patient as well as enabling informed genetic 
counselling for the wider family. In the future it would be incredibly useful to create 
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a diagnostic screening panel of common founder pathogenic variants within 
populations, such as Nablus, to aid in the management of affected individuals 







Through a community-based translational genetic medicine program based at the 
University of Exeter, four families from Nablus were recruited for genetic 
investigation. Each family consisted of at least two individuals with ID and a 
myriad of other clinical characteristics. Through genome-wide SNP mapping and 
whole exome sequencing, potential candidate genetic variants were identified. 
 
 
A novel mutation within an ARHGAP gene was identified and found to 
cosegregate within one of the families. A different variant within a different 
transcript of this gene was recently implemented within neurodevelopmental 
disorders, furthering the belief that this novel mutation is pathogenic. Ongoing 
functional studies into the ARHGAP variant as well as mouse model studies will 




A previously reported variant within ALG1 was found to cosegregate within 
another family. Mutations within ALG1 are known to cause a rare autosomal 
recessive congenital disorder of glycosylation (ALG1-CDG). ALG1-CDG is 
characterised by; microcephaly, developmental delay, abnormal fat distribution, 
strabismus, coagulation abnormalities, hypotonia, and failure to thrive. The three 
affected individuals within this family showed clinically similar characteristics to 
those of ALG1-CDG patients. Although the variant identified has been reported 
before, it is believed that this is the first time it has been reported in homozygous 
form. On-going clinical investigations will aid in confirming pathogenicity of the 
variant. 
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Two further families were found to harbor genetic duplications within one copy of 
a chromosome. One of these families possessed a duplication within 17q21.3, an 
area correlated with 17q21.31 duplication syndrome, the reciprocal Koolen- De 
Vries syndrome. Only a handful of patients with duplications within this region 
have been reported, all with similar clinical phenotypes to the affected individuals.  
Further research is required to reach a diagnosis within of the two families 
involved in this study, however through this collaborative program we have shown 
how important community-based research programmes are in defining the 








7.1 Primer Sequences 
 
Gene Name Forward Primer Reverse Primer 
ALG1 tgctctatggcctctcacag ctagacacccctcttccagc 
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